NCT04203316 2026-01-09Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationChildren's Oncology GroupPhase 2 Active not recruiting1 enrolled
NCT05441514 2025-09-16Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCity of Hope Medical CenterPhase 1 Active not recruiting3 enrolled